President Trump announced a drug pricing agreement with Regeneron, finalizing a series of deals with 17 manufacturers pressured to adopt his "most favored nation" policy. These agreements aim to lower prices for certain drugs offered to Medicaid and cash-paying patients, with the administration claiming they cover 86% of branded pharmaceuticals. However, policy experts and Democrats question the actual impact on consumers, noting that discounts may not significantly affect company profits and largely exclude those with private insurance or Medicare. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON This is a political/policy news item with a tangential mention of AI, not core AI news.
